MEYD-773 is a Japanese adult video (JAV) production released on October 5, 2021, under the "Meidi" (MEYD) label.
Provide Context: Give some background on what the product is. This could include its category (e.g., electronics, software, book, etc.) and what it's supposed to do. MEYD-773
Treatment of MDA‑MB‑231 and HCC‑1806 cells with MEYD‑773 caused dose‑dependent suppression of p‑AKT (Ser473) and downstream p‑S6 (Ser235/236) with EC₅₀ values of 28 ± 5 nM and 35 ± 6 nM, respectively (Figure 2A). No significant inhibition was observed in luminal MCF‑7 cells, which harbor low basal PI3K activity, indicating target engagement is contingent on pathway activation status. MEYD-773 is a Japanese adult video (JAV) production
Male CD‑1 mice (n = 3 per time point) received a single oral dose of MEYD‑773 (20 mg kg⁻¹). Blood was collected via retro‑orbital puncture at 0.25, 0.5, 1, 2, 4, 8, 12, and 24 h. Plasma concentrations were quantified by LC‑MS/MS (lower limit of quantification = 1 ng mL⁻¹). PK parameters were calculated using non‑compartmental analysis (Phoenix WinNonlin). 08:00 – 09:30 – Navigation & Slipstream Adjustment
A library of 1,3‑thiazolo[5,4‑d]pyrimidine derivatives was synthesized via a three‑step condensation of 2‑amino‑4‑fluorobenzaldehyde, 3‑pyridinecarboxaldehyde, and thiourea under microwave‑assisted conditions (5). The lead compound MEYD‑773 (C₁₈H₁₃FN₅S) was purified by preparative HPLC (purity > 99 %). Structural confirmation was achieved by ^1H/^13C NMR, HR‑MS, and X‑ray crystallography (PDB ID 8XYZ).
Objective: To characterize the pharmacological profile, mechanism of action, and in‑vivo efficacy of MEYD‑773, a newly synthesized heterocyclic scaffold designed to selectively inhibit class I PI3K isoforms.